What is King Pharmaceuticals's total equity?

King Pharmaceuticals (KG) reported total equity of $121.44M in Q1 2026.

How has King Pharmaceuticals's total equity changed year-over-year?

King Pharmaceuticals's total equity increased by 2772.9% year-over-year, from $4.23M to $121.44M.

What does total equity mean?

Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

King Pharmaceuticals KG Total Equity

Total Equity at other companies

Arch Capital GroupACGL

$24.19B+12.3%

Everest GroupEG

$15.29B+8.1%

SiriusPointSPNT

$2.3B+13.7%

KKR & Co.KKR

$30.5B+11.0%

Skyward Specialty Insurance Group, Inc.SKWD

$1.22B+44.0%

Tiptree Inc.TIPT

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's total equity?: King Pharmaceuticals (KG) reported total equity of $121.44M in Q1 2026.
How has King Pharmaceuticals's total equity changed year-over-year?: King Pharmaceuticals's total equity increased by 2772.9% year-over-year, from $4.23M to $121.44M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.